Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae

European Journal of Endocrinology

Volumn 163, Issue 4, 2010, Pages 531-539

  Bakhtiar, Yuriz ^a   Hirano, Hirofumi ^a   Arita, Kazunori ^a   Yunoue, Shunji ^a   Fujio, Shingo ^a   Tominaga, Atsushi ^b   Sakoguchi, Tetsuhiko ^b   Sugiyama, Kazuhiko ^b   Kurisu, Kaoru ^b   Yasufuku Takano, Junko ^c   Takano, Koji ^c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIBODY; CYTOKERATIN; GONADORELIN; OCTREOTIDE; PROTEIN P53; PROTIRELIN; UVOMORULIN; GROWTH HORMONE; KERATIN; SOMATOMEDIN C;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GROWTH HORMONE SECRETING ADENOMA; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; SCHOOL CHILD; TUMOR VOLUME; BLOOD; IN VITRO STUDY; METABOLISM; MICROSCOPY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; GROWTH HORMONE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; KERATINS; MALE; MICROSCOPY; MIDDLE AGED; YOUNG ADULT; IN VITRO TECHNIQUES;

EID: 77957173774     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0586     Document Type: Article

References (46)

1. Asa SL. Tumors of the pituitary gland. In Atlas of Tumor Pathology, Series 3, Fascicle 22, pp 47-131. Washington: Armed Forces Institute of Pathology, 1998.
2. Osamura RY, Tamara S, Curtain R, Sino N, Matsuno A & Teramoto A. Contributions of immunohistochemistry and hybridization to the functional analysis of pituitary adenomas. Journal of Histochemistry and Cytochemistry 2000 48 445-458.
3. Thapar K & Laws ER. Pituitary tumors: functioning and nonfunctioning. In Youmans Neurological Surgery, 5th edn, vol 1, pp 1169-1207. Eds HRWinn, R Sawaya & H Brem. Philadelphia: Saunders, 2004.
4. Horvath E & Kovacs K. The adenohypophysis. In Functional Endocrine Pathology, vol 1, pp 242-281. Eds K Kovacs & SL Asa. Boston, PA: Blackwell, 1991.
5. Kontogeorgos G, Watson Jr RE, Lindell EP, Barken AL, Farrell WE & Lloyd RV. Growth hormone producing adenoma. In Pathology and Genetics of Tumors of Endocrine Organs (World Health Organization Classification of Tumours series), pp 14-19. Eds RS DeLellis, RV Lloyd, PU Heitz & C Eng. Lyon, PA: IARC Press, 2004.
6. Horvath E & Kovacs K. Morphogenesis and significance of fibrous bodies in human pituitary adenomas. Virchows Archiv. B: Cell Pathology 1978 27 69-78. (doi:10.1007/BF02888984)
7. Yamada S, Aiba T, Sano T, Kovacs K, Shishiba Y, Kawano S & Takada K. Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 1993 33 20-27. (doi:10.1227/ 00006123-199307000-00003) (Pubitemid 23204807)
8. Nishioka H, Haraoka J & Akada K. Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenoma. Clinical Endocrinology 2003 59 768-772. (doi:10.1046/j.1365- 2265.2003.01921.x)
9. Obari A, Sano T, Oyama K, Kudo E, Qian ZR, Yoneda A, Nasim R, Rahman MM & Yamada S. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocrine Pathology 2008 19 82-91. (doi:10.1007/s12022-008-9029-z)
10. Sano T, Yamada S, Hirose T & Hirazawa K. Cytokeratin distribution and functional properties of growth hormone-producing pituitary adenomas. Endocrine Pathology 1994 5 107-113. (doi:10.1007/BF02921378)
11. Mazal PR, Czech T, Sedivy R, Aichholzer M, Wenschitz J, Klupp N & Budka H. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormonal expression profile and cell proliferation in pituitary adenomas of acromegalic patients. Clinical Neuropathology 2001 20 163-173.
12. Neumann PE, Goldman JE, Horoupian DS & Hess MA. Fibrous bodies in growth hormone-secreting adenomas contain cytokeratin filaments. Archives of Pathology & Laboratory Medicine 1985 109 505-508.
13. Kasper M, Stosiek P, Van Muijen GNP & Moll R. Cell type heterogeneity of intermediate filament expression in epithelia of the human pituitary gland. Histochemistry 1989 93 93-103. (doi:10.1007/BF00266853) (Pubitemid 19272708)
14. Toivola DM, Tao GZ, Habtezion A, Liao J & Omary MB. Cellular integrity plus organelle-related and protein-targeting functions on intermediate filaments. Trends in Cell Biology 2005 15 608-617. (doi:10.1016/j.tcb.2005.09. 004)
15. Chu PG & Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002 40 403-439. (doi:10.1046/j.1365-2559.2002.01387.x)
16. Vallar L, Spada A & Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987 330 566-568. (doi:10.1038/330566a0)
17. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR & Vallar L. GTPase inhibiting mutations activate the a chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989 340 692-696. (doi:10.1038/340692a0) (Pubitemid 19214389)
18. Yasufuku-Takano J, Takano K, Morita K, Takakura K, Teramoto A & Fujita T. Does the prevalence of gsp mutations in GH-secreting pituitary adenomas differ geographically or racially? Prevalence of gsp mutations in Japanese patients revisited Clinical Endocrinology 2006 64 91-96. (doi:10.1111/j.1365-2265.2005.02423.x)
19. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M & Faglia G. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumours with or without constitutively active adenylyl cyclase. Journal of Clinical Endocrinology and Metabolism 1990 71 1421-1426. (doi:10.1210/jcem-71-6-1421)
20. Landis CA, Harsh G, Lyons J, Davis RL, McCormick F & Bourne HR. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. Journal of Clinical Endocrinology and Metabolism 1990 71 1416-1420. (doi:10.1210/jcem-71-6-1416)
21. Harris PE, Alexander JM, Bikkal HA, Hsu DW, Hedley-Whyte ET, Klibanski A & Jameson JL. Glycoprotein hormone α-subunit production in somatotroph adenomas with and without Gs alpha mutations. Journal of Clinical Endocrinology and Metabolism 1992 75 918-923. (doi:10.1210/jc.75.3.918)
22. Buchfelder M, Fahlbusch R, Merz T, Symowski H & Adams EF. Clinical correlates in acromegalic patients with pituitary tumors expressing gsp oncogenes. Pituitary 1999 1 181-185. (doi:10.1023/A:1009905131334)
23. Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, Frank SJ & Ezzat S. A growth hormone receptor mutation impairs growth hormone auto feedback signaling in pituitary tumors. Cancer Research 2007 67 7505-7511. (doi:10.1158/0008-5472.CAN-07-0219)
24. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (doi:10.1210/jc.85.2.526) (Pubitemid 32273628)
25. Lundin P & Pedersen F. Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer Assisted Tomography 1992 16 519-528. (doi:10.1097/00004728-199207000-00004)
26. Knosp E, Steiner E, Kitz K & Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993 33 610-617. (doi:10.1227/00006123-199310000-00008)
27. Lehr HA, Folpe A, Yaziji H, Kommoss F & Gown AM. Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. American Journal of Clinical Pathology 2000 114 190-196. (doi:10.1309/CPUX-KWEH-7B26-YE19) (Pubitemid 33051866)
28. Amagai M, Fujimori T, Masunaga T, Shimizu H, Nishikawa T, Shimizu N, Takeichi M & Hashimoto T. Delayed assembly of desmosomes in keratinocytes with disrupted classic-cadherin-mediated cell adhesion by dominant negative mutant. Journal of Investigative Dermatology 1995 104 27-32. (doi:10.1111/1523-1747.ep12613462)
29. Takeichi M. Cadherin in cancer: implication for invasion and metastasis. Current Opinion in Cell Biology 1993 5 806-811. (doi:10.1016/0955-0674(93)90029- P)
30. Biermasz NR, Smit JW, van Dulken H & Roelfsema F. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. Clinical Endocrinology 2002 56 313-319. (doi:10.1046/j.1365-2265.2002.01465.x)
31. Igarashi-Migitaka J, Yamada S, Hara M, Sano T, Ozawa Y, Ohtani- Kaneko R & Hirata K. Gene expression study of thyrotropin releasing hormone (TRH) receptor using RT-PCR: relationship to clinical and immunohistochemical phenotypes in a series of human pituitary adenomas. Endocrine Journal 2003 50 459-467. (doi:10.1507/endocrj.50.459)
32. Hinkle PM & Tashjian AH Jr. Thyrotropin-releasing hormone regulates the number of its own receptors in the GH3 strain of pituitary cells in culture. Biochemistry 1975 14 3845-3851. (doi:10.1021/bi00688a017)
33. Winicov I & Gershengorn MC. Receptor density determines secretory response patterns mediate by inositol lipid-derived second messengers. Comparison of thyrotropin-releasing hormone and carbamylcholine actions in thyroid-stimulating hormone-secreting mouse pituitary tumour cells. Journal of Biological Chemistry 1989 264 9438-9443.
34. Tomić M, Zivadinovic D, Van Goor F, Yuan D, Koshimizu T & Stojilkovic SS. Expression of Ca(2+)-mobilizing endothelin (A) receptors and their role in the control of Ca(2+) influx and growth hormone secretion in pituitary somatotrophs. Journal of Neuroscience 1999 19 7721-7731. (Pubitemid 30225772)
35. Yang I, Park S, Ryu M, Woo J, Kim S, Kim J, Kim Y & Choi Y. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. European Journal of Endocrinology 1996 134 720-726. (doi:10.1530/eje.0.1340720)
36. Gershengorn MC & Thaw CN. Regulation of thyrotropin-releasing hormone receptors is cell type specific: comparison of endogenous pituitary receptors and receptors transfected into non-pituitary cells. Endocrinology 1991 128 1204-1206. (doi:10.1210/endo-128-2-1204)
37. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG & Collins MT. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 5104-5112. (doi:10.1210/jc.2001-012022)
38. Bhayana S, Booth GL, Asa SL, Kovacs K & Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 6290-6295. (doi:10.1210/jc.2005-0998)
39. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG & Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. European Journal of Endocrinology 1995 133 686-690. (doi:10.1530/eje.0.1330686)
40. Patel YC, Greenwood M, Kent G, Panetta R & Srikant CB. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochemical and Biophysical Research Communications 1993 192 288-294. (doi:10.1006/bbrc.1993.1412)
41. Nakashima M, Takano K & Matsuno A. Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas. Endocrine Journal 2009 56 295-304. (doi:10.1507/endocrj.K08E-305)
42. Nishioka H & Haraoka J. Biochemical cure of acromegaly after transsphenoidal surgery despite residual tumor on magnetic resonance imaging - case report. Neurologia Medico-Chirurgica 2008 48 311-313. (doi:10.2176/nmc.48. 311)
43. Hosoi E, Yokogoshi Y, Hosoi E, Horie H, Sano T, Yamada S & Saito S. Analysis of the Gs alpha gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues. Acta Endocrinologica 1993 129 301-306. (doi:10.1530/acta.0.1290301) (Pubitemid 23319220)
44. Yoshimoto K, Iwahana H, Fukuda A, Sano T & Itakura M. Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer- introduced restriction analysis. Cancer 1993 72 1386-1393. (doi:10.1002/1097-0142(19930815)72:4〈1386::AID- CNCR2820720439〉3.0.CO;2-J)
45. Yamasaki H, Mizusawa N, Nagahiro S, Yamada S, Sano T, Itakura M & Yoshimoto K. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23-24. Clinical Endocrinology 2003 58 464-470. (doi:10.1046/j.1365-2265.2003.01740.x)
46. Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M & Fahlbusch R. Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery 1993 33 198-203. (doi:10.1227/00006123-199308000-00003)